DRAGONFLY's mission is to revolutionize disease treatment by developing advanced immunotherapies for vastly improved patient outcomes.
​
We build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation and beyond.
In collaboration with AbbVie, BMS, Gilead and Merck, our platform has generated drug candidates to target challenging diseases in a variety of therapeutic areas.
Engaging the Immune
System to Fight Disease
Our Collaborations
DRAGONFLY is an effective pharma partner.
Dragonfly rapidly develops drugs with our pharma partners in expanding fields including autoimmune disease, oncology, neuro-inflammation and beyond.
Growing the
Pipeline for Patients
In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing novel immune engagers in a range of fields, including autoimmune and inflammatory diseases, fibrosis and oncology.
DRAGONFLY's pipeline is growing in a number of
therapeutic areas of critical patient need.
